BMC Cancer: For locally advanced esophageal cancer, such as cT1N+ and cT2Nany, is neoadjuvant therapy or adjuvant therapy better?

For locally advanced esophageal cancer, it is currently recommended to use neoadjuvant therapy + surgery
.

Due to the inaccuracy of clinical staging, especially for patients with cT1N+ and cT2N _any esophageal cancer, some doctors suggest to consider post-surgery + adjuvant treatment

For locally advanced esophageal cancer, it is currently recommended to use neoadjuvant therapy + surgery

We used the National Cancer Database (2006-2015) for all accepted esophageal resection cT1N + and cT2N _{the any} of esophageal cancer patients were analyzed
.

The treatment groups are: neoadjuvant therapy (NT), adjuvant therapy (AT), and neoadjuvant therapy + adjuvant therapy (CT) group combination therapy, and the results are analyzed

We used the National Cancer Database (2006-2015) for all accepted esophageal resection cT1N + and cT2N _{the any} of esophageal cancer patients were analyzed

The study included 2795 patients, of which 81.

9% (n=2289) received NT, 10.

The study included 2795 patients, of which 81.

Complications and mortality of the three treatment groups

Complications and mortality of the three groups of treatments Complications and mortality of the three groups of treatments

Using Cox regression model for multivariate analysis, there was no significant difference in OS between cT1N+ and cT2Nany patients in the AT group and the NT group (cT1N+(P=0.
344), cT2N-(P=0.
473), cT2N+(P=0.
280))
.

There was no significant difference in OS between CT group and NT group (cT1N+(P=0.

Using Cox regression model for multivariate analysis, there was no significant difference in OS between cT1N+ and cT2Nany patients in the AT group and the NT group (cT1N+(P=0.

Analysis of OS difference in the three treatment groups

Analysis of OS difference in thethree treatment groups Analysis of OS difference in the three treatment groups

In the neoadjuvant therapy (NT) group, 92.
8% of patients received chemotherapy and radiotherapy, 6.
5% of patients received chemotherapy, and 0.
7% of patients received radiotherapy; in the NT group, compared with neoadjuvant radiotherapy alone, neoadjuvant chemotherapy and neoadjuvant radiotherapy There was a better OS trend in the adjuvant radiotherapy and chemotherapy group, but the difference was not statistically significant (P=0.
377, P= 0.
311)
.

There was no difference in OS between neoadjuvant chemoradiation and neoadjuvant chemotherapy alone (P=0.

In the neoadjuvant therapy (NT) group, 92.

          Differences in OS of different treatment options in the neoadjuvant therapy (NT) group

          The difference in OS between different treatment options in the neoadjuvant treatment (NT) group The difference in OS between different treatment options in the neoadjuvant treatment (NT) group

In the adjuvant therapy (AT) group, 58.
6% of patients received chemotherapy and radiotherapy, 37.
9% of patients received chemotherapy, and 3.
5% of patients received radiotherapy
.

Compared with adjuvant radiotherapy alone, both adjuvant chemotherapy and adjuvant radiotherapy and chemotherapy groups had a survival benefit (P<0.
005; P=0.
010)
.
However, there was no significant difference in overall survival between adjuvant chemotherapy and radiotherapy alone (P=0.
476)
.

In the adjuvant therapy (AT) group, 58.
6% of patients received chemotherapy and radiotherapy, 37.
9% of patients received chemotherapy, and 3.
5% of patients received radiotherapy
.
Compared with adjuvant radiotherapy alone, both adjuvant chemotherapy and adjuvant radiotherapy and chemotherapy groups had a survival benefit (P<0.
005; P=0.
010)
.
However, there was no significant difference in overall survival between adjuvant chemotherapy and radiotherapy alone (P=0.
476)
.
In the adjuvant therapy (AT) group, 58.
6% of patients received chemotherapy and radiotherapy, 37.
9% of patients received chemotherapy, and 3.
5% of patients received radiotherapy
.
Compared with adjuvant radiotherapy alone, both adjuvant chemotherapy and adjuvant radiotherapy and chemotherapy groups had a survival benefit (P<0.
005; P=0.
010)
.
However, there was no significant difference in overall survival between adjuvant chemotherapy and radiotherapy alone (P=0.
476)
.

              Differences in OS of different treatment options in the adjuvant therapy (AT) group

              OS difference of different treatment options in the adjuvant treatment (AT) group OS difference of different treatment options in the adjuvant treatment (AT) group

 

In summary, studies have shown that NT has no obvious advantage over AT in patients with cT1N+ and cT2N _any esophageal cancer
.
Adjuvant treatment after surgery can be considered another option for these patients
.
Further prospective studies are needed to verify these findings
.

In summary, studies have shown that NT has no obvious advantage over AT in patients with cT1N+ and cT2N _any esophageal cancer
.
Adjuvant treatment after surgery can be considered another option for these patients
.
Further prospective studies are needed to verify these findings
.
In summary, the study showed that studies show that research shows that, in cT1N +, cT2N _{the any} of esophageal cancer patients, NT AT contrast no obvious advantage
.
Adjuvant treatment after surgery can be considered another option for these patients
.
Further prospective studies are needed to verify these findings
.
In patients with cT1N+ and cT2N _any esophageal cancer, NT has no obvious advantage over AT
.
Adjuvant treatment after surgery can be considered another option for these patients
.
Further prospective studies are needed to verify these findings
.
_any

 

Original source:

Original source:

Huang B, Chan EG, Pennathur A, Luketich JD, Zhang J.
The ideal approach for treatment of cT1N+ and cT2Nany esophageal cancer.
: a NCDB analysis.
BMC Cancer.
2021 Dec 15;21(1):1334.
doi: 10.
1186/ s12885-021-08896-0.
PMID: 34911468; PMCID: PMC8672500.

Huang B, Chan EG, Pennathur A, Luketich JD, Zhang J.
The ideal approach for treatment of cT1N+ and cT2Nany esophageal cancer.
: a NCDB analysis.
BMC Cancer.
2021 Dec 15;21(1):1334.
doi: 10.
1186/ s12885-021-08896-0.
PMID: 34911468; PMCID: PMC8672500.
Leave a message here